Trends in secondary antibiotic resistance of helicobacter pylori from 2007 to 2014: Has the tide turned?

Journal of Clinical Microbiology

Volumn 53, Issue 2, 2015, Pages 522-527

  Boltin, Doron ^a,b   Ben Zvi, Haim ^a   Perets, Tsachi Tsadok ^a   Kamenetsky, Zvi ^a   Samra, Zmira ^a   Dickman, Ram ^a   Niv, Yaron ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; ANTIINFECTIVE AGENT;

ADULT; AGE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CLEARANCE; BACTERIUM CULTURE; BACTERIUM ISOLATION; BIRTHPLACE; DRUG TREATMENT FAILURE; FEMALE; GASTROSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PREDICTION; RETROSPECTIVE STUDY; SECONDARY ANTIBIOTIC RESISTANCE; TREND STUDY; AGED; DRUG EFFECTS; HELICOBACTER INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PREVALENCE; TIME FACTOR; YOUNG ADULT;

HELICOBACTER PYLORI;

ADULT; AGE FACTORS; AGED; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LEVOFLOXACIN; MALE; METRONIDAZOLE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84921776834     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03001-14     Document Type: Article

References (40)

1. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon Anthony TR, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. 2012. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 61:646-664. http://dx.doi.org/10.1136/gutjnl-2012-302084.
2. Graham DY, Lee Y, Wu M. 2014. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 12:177-186. e3; Discussion e12-e13. http://dx.doi.org/10.1016/j.cgh.2013.05.028.
3. Gao W, Cheng H, Hu F, Li J, Wang L, Yang G, Xu L, Zheng X. 2010. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter 15:460-466. http://dx.doi.org/10.1111/j.1523-5378.2010.00788.x.
4. Raymond J, Lamarque D, Kalach N, Chaussade S, Burucoa C. 2010. High level of antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter 15:21-27. http://dx.doi.org/10.1111/j.1523-5378.2009.00737.x.
5. Glupczynski Y, Mégraud F, Lopez-Brea M, Andersen LP. 2001. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 20:820-823. http://dx.doi.org/10.1007/s100960100611.
6. Osato MS, Reddy R, Reddy SG, Penland RL, Graham DY. 2001. Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int J Antimicrob Agents 17:39-44. http://dx.doi.org/10.1016/S0924-8579(00)00320-4.
7. EUCAST. 2011. EUCAST clinical breakpoints for Helicobacter pylori. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Breakpoint-tables/Breakpoint-table-v-4.0.pdf
8. King A. 2001. Recommendations for susceptibility tests on fastidious organisms and those requiring special handling. J Antimicrob Chemother 48(Suppl 1):77-80. http://dx.doi.org/10.1093/jac/48.suppl-1.77.
9. Tankovic J, Lascols C, Sculo Q, Petit J, Soussy C. 2003. Single and double mutations in gyrA but not in gyrB are associated with low-and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 47:3942-3944. http://dx.doi.org/10.1128/AAC.47.12.3942-3944.2003.
10. Mégraud F, Lehn N, Lind T, Bayerdörffer E, O'Morain C, Spiller R, Unge P, van Zanten SV, Wrangstadh M, Burman CF. 1999. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 43:2747-2752.
11. Janssen MJR, Hendrikse L, de Boer SY, Bosboom R, de Boer WA, Laheij RJF, Jansen JBMJ. 2006. Helicobacter pylori antibiotic resistance in a Dutch region: trends over time. Neth J Med 64:191-195.
12. Kalach N, Serhal L, Asmar E, Campeotto F, Bergeret M, Dehecq E, Spyckerelle C, Charkaluk M, Decoster A, Dupont C, Raymond J. 2007. Helicobacter pylori primary resistant strains over 11 years in French children. Diagn Microbiol Infect Dis 59:217-222. http://dx.doi.org/10.1016/j.diagmicrobio.2007.05.003.
13. Boyanova L, Nikolov R, Gergova G, Evstatiev I, Lazarova E, Kamburov V, Panteleeva E, Spassova Z, Mitov I. 2010. Two-decade trends in primary Helicobacter pylori resistance to antibiotics in Bulgaria. Diagn Microbiol Infect Dis 67:319-326. http://dx.doi.org/10.1016/j.diagmicrobio.2010.03.010.
14. Miendje Deyi VY, Bontems P, Vanderpas J, de Koster E, Ntounda R. Van den Borre C, Cadranel S, Burette A. 2011. Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium. J Clin Microbiol 49:2200-2209. http://dx.doi.org/10.1128/JCM.02642-10.
15. Karlowsky JA, Lagacé-Wiens Philippe RS, Low DE, Zhanel GG. 2009. Annu macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005. Int J Antimicrob Agents 34:375-379. http://dx.doi.org/10.1016/j.ijantimicag.2009.05.008.
16. Adriaenssens N, Coenen S, Versporten A, Muller A, Minalu G, Faes C, Vankerckhoven V, Aerts M, Hens N, Molenberghs G, Goossens H. 2011. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997-2009). J Antimicrob Che-mother 66(Suppl 6):vi3-vi12. http://dx.doi.org/10.1093/jac/dkr453.
17. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y. 2013. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62:34-42. http://dx.doi.org/10.1136/gutjnl-2012-302254.
18. Muhsen K, Cohen D, Spungin-Bialik A, Shohat T. 2012. Seroprevalence, correlates and trends of Helicobacter pylori infection in the Israeli population. Epidemiol Infect 140:1207-1214. http://dx.doi.org/10.1017/S0950268811002081.
19. Samra Z, Shmuely H, Niv Y, Dinari G, Passaro DJ, Geler A, Gal E, Fishman M, Bachor J, Yahav J. 2002. Resistance of Helicobacter pylori isolated in Israel to metronidazole, clarithromycin, tetracycline, amoxicil-lin and cefixime. J Antimicrob Chemother 49:1023-1026. http://dx.doi.org/10.1093/jac/dkf041.
20. Zevit N, Levy I, Shmuely H, Samra Z, Yahav J. 2010. Antibiotic resistance of Helicobacter pylori in Israeli children. Scand J Gastroenterol 45: 550-555. http://dx.doi.org/10.3109/00365521003663688.
21. Yahav J, Shmuely H, Niv Y, Bechor J, Samra Z. 2006. In vitro activity of levofloxacin against Helicobacter pylori isolates from patients after treatment failure. Diagn Microbiol Infect Dis 55:81-83. http://dx.doi.org/10.1016/j.diagmicrobio.2005.12.003.
22. Nitzan O, Low M, Lavi I, Hammerman A, Klang S, Raz R. 2010. Variability in outpatient antimicrobial consumption in Israel. Infection 38:12-18. http://dx.doi.org/10.1007/s15010-009-9065-8.
23. Low M, Nitzan O, Bitterman H, Cohen C, Hammerman A, Lieberman N, Raz R, Balicer RD. 2013. Trends in outpatient antibiotic use in Israel during the years 2000-2010: setting targets for an intervention. Infection 41:401-407. http://dx.doi.org/10.1007/s15010-012-0332-8.
24. Agudo S, Perez-Perez G, Alarcon T, Lopez-Brea M. 2010. High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistanceinMadrid, Spain. JClin Microbiol 48:3703-3707. http://dx.doi.org/10.1128/JCM.00144-10.
25. Alarcón T, Vega AE, Domingo D, Martinez MJ, Lopez-Brea M. 2003. Clarithromycin resistance among Helicobacter pylori strains isolated from children: prevalence and study of mechanism of resistance by PCR-restriction fragment length polymorphism analysis. J Clin Microbiol 41: 486-499. http://dx.doi.org/10.1128/JCM.41.1.486-488.2003.
26. Cabrita J. 2000. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 46:1029-1031. http://dx.doi.org/10.1093/jac/46.6.1029.
27. Tolia V, Brown W, El-Baba M, Lin CH. 2000. Helicobacter pylori culture and antimicrobial susceptibility from pediatric patients in Michigan. Pe-diatr Infect Dis J 19:1167-1171. http://dx.doi.org/10.1097/00006454-200012000-00010.
28. Koletzko S, Richy F, Bontems P, Crone J, Kalach N, Monteiro ML, Gottrand F, Celinska-Cedro D, Roma-Giannikou E, Orderda G, Kolacek S, Urruzuno P, Martínez-Gómez MJ, Casswall T, Ashorn M, Bodanszky H, Mégraud F. 2006. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 55:1711-1716. http://dx.doi.org/10.1136/gut.2006.091272.
29. Kobayashi I, Murakami K, Kato M, Kato S, Azuma T, Takahashi S, Uemura N, Katsuyama T, Fukuda Y, Haruma K, Nasu M, Fujioka T. 2007. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 45:4006-4010. http://dx.doi.org/10.1128/JCM.00740-07.
30. Prazeres Magalhães P, De Magalhães Queiroz DM, Campos Barbosa DV, Aguiar Rocha G, Nogueira Mendes E, Santos A, Valle Corrêa PR, Camargos Rocha AM, Martins TL, Affonso de Oliveira C. 2002. Heli-cobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. Antimicrob Agents Chemother 46:2021-2023. http://dx.doi.org/10.1128/AAC.46.6.2021-2023.2002.
31. Larsen AL, Ragnhildstveit E, Moayeri B, Eliassen L, Melby KK. 2013. Resistance rates of metronidazole and other antibacterials in Helicobacter pylori from previously untreated patients in Norway. APMIS 121:353-358. http://dx.doi.org/10.1111/apm.12009.
32. van Zwet AA, Thijs JC, Graaf de B. 1995. Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains. Antimicrob Agents Chemother 39:250-252. http://dx.doi.org/10.1128/AAC.39.1.250.
33. van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. 1999. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 94:1751-1759. http://dx.doi.org/10.1111/j.1572-0241.1999.01202.x.
34. Graham DY. 1998. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 115:1272-1277. http://dx.doi.org/10.1016/S0016-5085(98)70100-3.
35. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. 2013. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 88:33-45. http://dx.doi.org/10.1159/000350719.
36. Malfertheiner P, Bazzoli F, Delchier J, Celinski K, Giguere M, Riviere M, Megraud F. 2011. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 377:905-913. http://dx.doi.org/10.1016/S0140-6736(11)60020-2.
37. Xiong LJ, Tong Y, Wang Z, Mao M. 2013. Detection of clarithromycin-resistant Helicobacter pylori by stool PCR in children: a comprehensive review of literature. Helicobacter 18:89-101. http://dx.doi.org/10.1111/hel.12016.
38. Tay CY, Windsor HM, Thirriot F, Lu W, Conway C, Perkins TT, Marshall BJ. 2012. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. Aliment Pharmacol Ther 36:1076-1083. http://dx.doi.org/10.1111/apt.12089.
39. D'Elios MM, Silvestri E, Emmi G, Barnini T, Prisco D. 2012. Helico-bacter pylori: usefulness of an empirical fourth-line rifabutin-based regimen. Expert Rev Gastroenterol Hepatol 6:437-439. http://dx.doi.org/10.1586/egh.12.32.
40. Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. 2011. A randomized study comparing levofloxacin, omeprazole, nitazox-anide, and doxycycline versus triple therapy for the eradication of Helico-bacter pylori. Am J Gastroenterol 106:1970-1975. http://dx.doi.org/10.1038/ajg.2011.306.